|
1
|
Miao K, Liu W, Xu J, Qian Z and Zhang Q:
Harnessing the power of traditional Chinese medicine monomers and
compound prescriptions to boost cancer immunotherapy. Front
Immunol. 14:12772432023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang K, Chen Q, Shao Y, Yin S, Liu C, Liu
Y, Wang R, Wang T, Qiu Y and Yu H: Anticancer activities of TCM and
their active components against tumor metastasis. Biomed
Pharmacother. 133:1110442021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang H and Gu J: Progress of experimental
study on treatment of psoriasis by Chinese medicinal monomer and
single or compound recipe in Chinese materia medica. Chin J Integr
Med. 13:312–316. 2007. View Article : Google Scholar
|
|
4
|
Liang J, Zhu Y, Liu S, Kuang B, Tian Z,
Zhang L, Yang S, Lin M, Chen N, Liu X, et al: Progress of exosomal
MicroRNAs and traditional Chinese medicine monomers in
neurodegenerative diseases. Phytother Res. 38:5323–5349. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lv D, Liu Y, Tang R, Fu S, Kong S, Liao Q,
Li H and Lin L: Analysis of clinical trials using anti-tumor
traditional Chinese medicine monomers. Drug Des Devel Ther.
18:1997–2020. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu X, Zhang Y, Yi F, Geng Z, Guo M, Ling
X, Li J and Li L: Anti-inflammatory and barrier repair mechanisms
of active components in Daemonorops draco Bl. for UVB-induced skin
damage. Sci Rep. 15:171242025. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pan Y, Wu W, Jiang X and Liu Y:
Mesenchymal stem cell-derived exosomes in cardiovascular and
cerebrovascular diseases: From mechanisms to therapy. Biomed
Pharmacother. 163:1148172023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen C, Ai Q, Tian H and Wei Y: CKLF1 in
cardiovascular and cerebrovascular diseases. Int Immunopharmacol.
139:1127182024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu C, Du L, Wang S, Kong L, Zhang S, Li
S, Zhang W and Du G: Differences in the prevention and control of
cardiovascular and cerebrovascular diseases. Pharmacol Res.
170:1057372021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang S, Yin X, Jiang T, Xu J and Wang D:
Impact of cardiovascular and cerebrovascular diseases mortality on
life expectancy in tianjin, 2004 and 2020. Asia Pac J Public
Health. 36:455–462. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Luan J and Zhai G: Targeted drug delivery
for cardiovascular and cerebrovascular diseases. Curr Drug Targets.
17:467–474. 2016. View Article : Google Scholar
|
|
12
|
Lan Q, Chen L, Chen MT, Wan ZX, Peng T,
Mazhar M, Liu P, Luo G, Jiang Y and Liu MN: Salvia miltiorrhiza:
Insights on the protective effect and mechanism of myocardial
ischemia-reperfusion injury. Braz J Med Biol Res. 58:e147232025.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li ZM, Xu SW and Liu PQ: Salvia
miltiorrhizaBurge (Danshen): A golden herbal medicine in
cardiovascular therapeutics. Acta Pharmacol Sin. 39:802–824. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wei B, Sun C, Wan H, Shou Q, Han B, Sheng
M, Li L and Kai G: Bioactive components and molecular mechanisms of
Salvia miltiorrhiza Bunge in promoting blood circulation to remove
blood stasis. J Ethnopharmacol. 317:1166972023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim MS, Bang JH, Lee J, Kim HW, Sung SH,
Han JS and Jeon WK: Salvia miltiorrhiza extract protects white
matter and the hippocampus from damage induced by chronic cerebral
hypoperfusion in rats. BMC Complement Altern Med. 15:4152015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jiang Z, Gao W and Huang L: Tanshinones,
critical pharmacological components in salvia miltiorrhiza. Front
Pharmacol. 10:2022019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pang H, Wu L, Tang Y, Zhou G, Qu C and
Duan JA: Chemical analysis of the herbal medicine salviae
miltiorrhizae radix et rhizoma (Danshen). Molecules. 21:512016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ma XH, Ma Y, Tang JF, He YL, Liu YC, Ma
XJ, Shen Y, Cui GH, Lin HX, Rong QX, et al: The biosynthetic
pathways of tanshinones and phenolic acids in Salvia miltiorrhiza.
Molecules. 20:16235–16254. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang X, Yang Y, Liu X and Gao X:
Pharmacological properties of tanshinones, the natural products
from Salvia miltiorrhiza. Adv Pharmacol. 87:43–70. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shi MJ, Dong BS, Yang WN, Su SB and Zhang
H: Preventive and therapeutic role of Tanshinone ⅡA in hepatology.
Biomed Pharmacother. 112:1086762019. View Article : Google Scholar
|
|
21
|
Guo R, Li L, Su J, Li S, Duncan SE, Liu Z
and Fan G: Pharmacological activity and mechanism of tanshinone IIA
in related diseases. Drug Des Devel Ther. 14:4735–4748. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhong C, Lin Z, Ke L, Shi P, Li S, Huang
L, Lin X and Yao H: Recent research progress (2015-2021) and
perspectives on the pharmacological effects and mechanisms of
tanshinone IIA. Front Pharmacol. 12:7788472021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li Z, Zou J, Cao D and Ma X:
Pharmacological basis of tanshinone and new insights into
tanshinone as a multitarget natural product for multifaceted
diseases. Biomed Pharmacother. 130:1105992020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Du L, Guan C, Zhang H, Jia H and Wan Q:
Harnessing the therapeutic value of Tanshinone IIA: A breakthrough
therapy in cardiovascular diseases. Front Pharmacol.
16:16201522025. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fu L, Han B, Zhou Y, Ren J, Cao W, Patel
G, Kai G and Zhang J: The anticancer properties of tanshinones and
the pharmacological effects of their active ingredients. Front
Pharmacol. 11:1932020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lu TC, Wu YH, Chen WY and Hung YC:
Targeting oxidative stress and endothelial dysfunction using
tanshinone IIA for the treatment of tissue inflammation and
fibrosis. Oxid Med Cell Longev. 2022:28117892022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cao Y, Tang H, Wang G, Li P, Song Z, Li W,
Sun X, Zhong X, Yu Q, Zhu S and Zhu L: Targeting survivin with
Tanshinone IIA inhibits tumor growth and overcomes chemoresistance
in colorectal cancer. Cell Death Discov. 9:3512023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jiang Y, Bi Y, Zhou L, Zheng S, Jian T and
Chen J: Tanshinone IIA inhibits proliferation and migration by
downregulation of the PI3K/Akt pathway in small cell lung cancer
cells. BMC Complement Med Ther. 24:682024. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Luo N, Zhang K, Li X, Hu Y and Guo L:
Tanshinone IIA destabilizes SLC7A11 by regulating PIAS4-mediated
SUMOylation of SLC7A11 through KDM1A, and promotes ferroptosis in
breast cancer. J Adv Res. 69:313–327. 2025. View Article : Google Scholar :
|
|
30
|
Lee AR, Wu WL, Chang WL, Lin HC and King
ML: Isolation and bioactivity of new tanshinones. J Nat Prod.
50:157–160. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wu WY and Wang YP: Pharmacological actions
and therapeutic applications of Salvia miltiorrhiza depside salt
and its active components. Acta Pharmacol Sin. 33:1119–1130. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fan G, Jiang X, Wu X, Fordjour PA, Miao L,
Zhang H, Zhu Y and Gao X: Anti-inflammatory activity of tanshinone
IIA in LPS-Stimulated RAW264.7 Macrophages via miRNAs and
TLR4-NF-κB pathway. Inflammation. 39:375–384. 2016. View Article : Google Scholar
|
|
33
|
Li YI, Elmer G and Leboeuf RC: Tanshinone
IIA reduces macrophage death induced by hydrogen peroxide by
upregulating glutathione peroxidase. Life Sci. 83:557–562. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li X, Park SJ, Jin F, Deng Y, Yang JH,
Chang JH, Kim DY, Kim JA, Lee YJ, Murakami M, et al: Tanshinone IIA
suppresses FcεRI-mediated mast cell signaling and anaphylaxis by
activation of the Sirt1/LKB1/AMPK pathway. Biochem Pharmacol.
152:362–372. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Maione F, De Feo V, Caiazzo E, De Martino
L, Cicala C and Mascolo N: Tanshinone IIA, a major component of
Salvia milthorriza Bunge, inhibits platelet activation via Erk-2
signaling pathway. J Ethnopharmacol. 155:1236–1242. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fan Y, Kang S, Shao T, Xu L and Chen J:
Activation of SIRT3 by Tanshinone IIA ameliorates renal fibrosis by
suppressing the TGF-β/TSP-1 pathway and attenuating oxidative
stress. Cell Signal. 122:1113482024. View Article : Google Scholar
|
|
37
|
Guo G, Zhao Q, Wang Q and Li E: Tanshinone
IIA ameliorate coxsackie virus B3-induced viral myocarditis through
the inhibition of inflammation and modulation T Helper 1/T Helper 2
balance in mice. Pharmacology. 103:136–142. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang P, Gu Y, Lu J, Song M, Hou W, Li P,
Sun Y, Wang J and Chen X: Endothelial TRPV4 channel mediates the
vasodilation induced by Tanshinone IIA. Chem Biol Interact.
402:1111812024. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Huang N, Li Y, Zhou Y, Zhou Y, Feng F, Shi
S, Ba Z and Luo Y: Neuroprotective effect of tanshinone
IIA-incubated mesenchymal stem cells on Aβ(25-35)-induced
neuroinflammation. Behav Brain Res. 365:48–55. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dinarello CA: Anti-inflammatory agents:
Present and future. Cell. 140:935–950. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li Y and Zhou Y: The therapeutic effect of
tanshinone IIA on propionibacterium acnes-induced inflammation in
vitro. Dermatol Ther. 31:e127162018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yang C, Lei X and Li J: Tanshinone IIA
reduces oxidized low-density lipoprotein-induced inflammatory
responses by downregulating microRNA-33 in THP-1 macrophages. Int J
Clin Exp Pathol. 12:3791–3798. 2019.
|
|
43
|
Filomeni G, De Zio D and Cecconi F:
Oxidative stress and autophagy: the clash between damage and
metabolic needs. Cell Death Differ. 22:377–388. 2015. View Article : Google Scholar :
|
|
44
|
Xu S, Liu Z, Huang Y, Le K, Tang F, Huang
H, Ogura S, Little PJ, Shen X and Liu P: Tanshinone II-A inhibits
oxidized LDL-induced LOX-1 expression in macrophages by reducing
intracellular superoxide radical generation and NF-κB activation.
Transl Res. 160:114–124. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Feng J, Li S and Chen H: Tanshinone IIA
inhibits myocardial remodeling induced by pressure overload via
suppressing oxidative stress and inflammation: Possible role of
silent information regulator 1. Eur J Pharmacol. 791:632–639. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang X, Wang WM, Han H, Zhang Y, Liu JL,
Yu JY, Liu HM, Liu XT, Shan H and Wu SC: Tanshinone IIA protected
against lipopolysaccharide-induced brain injury through the
protective effect of the blood-brain barrier and the suppression of
oxidant stress and inflammatory response. Food Funct. 13:8304–8312.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Elmore S: Apoptosis: A review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zhang Z, Li Y, Sheng C, Yang C, Chen L and
Sun J: Tanshinone IIA inhibits apoptosis in the myocardium by
inducing microRNA-152-3p expression and thereby downregulating
PTEN. Am J Transl Res. 8:3124–3132. 2016.PubMed/NCBI
|
|
49
|
Song T, Yao Y, Wang T, Huang H and Xia H:
Tanshinone IIA ameliorates apoptosis of myocardiocytes by
up-regulation of miR-133 and suppression of Caspase-9. Eur J
Pharmacol. 815:343–350. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang L, Wu Y, Li Y, Xu C, Li X, Zhu D,
Zhang Y, Xing S, Wang H, Zhang Z and Shan H: Tanshinone IIA
improves miR-133 expression through MAPK ERK1/2 pathway in hypoxic
cardiac myocytes. Cell Physiol Biochem. 30:843–852. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yan SH, Zhao NW, Geng ZR, Shen JY, Liu FM,
Yan D, Zhou J, Nie C, Huang CC and Fang ZY: Modulations of
Keap1-Nrf2 signaling axis by TIIA ameliorated the oxidative
stress-induced myocardial apoptosis. Free Radic Biol Med.
115:191–201. 2018. View Article : Google Scholar
|
|
52
|
Bellanti JA and Settipane RA: Allergy and
immunology: At the crossroad of inflammation and disease. Allergy
Asthma Proc. 44:1–2. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Costanzo G, Marchetti M, Ledda AG,
Sambugaro G, Bullita M, Paoletti G, Heffler E, Firinu D and
Costanzo GAML: Mast cells in allergic and non-allergic upper
airways diseases: Sentinel in the watchtower. Int J Mol Sci.
25:126152024. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kaminuma O, Nishimura T, Saeki M, Mori A
and Hiroi T: T cell-mediated nasal hyperresponsiveness in allergic
rhinitis. Biol Pharm Bull. 43:36–40. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Méndez-Enríquez E and Hallgren J: Mast
cells and their progenitors in allergic asthma. Front Immunol.
10:8212019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Thangam EB, Jemima EA, Singh H, Baig MS,
Khan M, Mathias CB, Church MK and Saluja R: The role of histamine
and histamine receptors in mast cell-mediated allergy and
inflammation: The hunt for new therapeutic targets. Front Immunol.
9:18732018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zhang J, Xie X, Ma R and Liu P: The role
of mast cells in allergic rhinitis. PeerJ. 13:e197342025.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Asada Y, Yamashita A, Sato Y and
Hatakeyama K: Thrombus formation and propagation in the onset of
cardiovascular events. J Atheroscler Thromb. 25:653–664. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Fei YX, Wang SQ, Yang LJ, Qiu YY, Li YZ,
Liu WY, Xi T, Fang WR and Li YM: Salvia miltiorrhiza Bunge
(Danshen) extract attenuates permanent cerebral ischemia through
inhibiting platelet activation in rats. J Ethnopharmacol.
207:57–66. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Jiang Y, Hu F, Li M and Li Q: Tanshinone
IIA ameliorates the development of dermal fibrosis in systemic
sclerosis. Clin Exp Pharmacol Physiol. 51:e138342024. View Article : Google Scholar
|
|
61
|
Wang DT, Huang RH, Cheng X, Zhang ZH, Yang
YJ and Lin X: Tanshinone IIA attenuates renal fibrosis and
inflammation via altering expression of TGF-β/Smad and NF-κB
signaling pathway in 5/6 nephrectomized rats. Int Immunopharmacol.
26:4–12. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Liao W, Wu F, Hao Z, Ye R, Liu C, Wu J, Wu
M, Zhou X, Sun M, Liu Y and Fang M: Tanshinone IIA alleviates liver
fibrosis by suppressing hepatic stellate cell proliferation via
ERK/cyclin D1/p-Smad3L signaling axis. Iran J Basic Med Sci.
28:638–646. 2025.PubMed/NCBI
|
|
63
|
Li Q, Huang D, Liao W, Su X, Li J, Zhang
J, Fang M and Liu Y: Tanshinone IIA regulates CCl(4) induced liver
fibrosis in C57BL/6J mice via the PI3K/Akt and Nrf2/HO-1 signaling
pathways. J Biochem Mol Toxicol. 38:e236482024. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Ren X, Wang C, Xie B, Hu L, Chai H, Ding
L, Tang L, Xia Y and Dou X: Tanshinone IIA induced cell death via
miR30b-p53-PTPN11/SHP2 signaling pathway in human hepatocellular
carcinoma cells. Eur J Pharmacol. 796:233–241. 2017. View Article : Google Scholar
|
|
65
|
Liu J, Zhang C, Liu S, Wang X, Wu X and
Hao J: Tanshinone IIA promotes apoptosis by downregulating BCL2 and
upregulating TP53 in triple-negative breast cancer. Naunyn
Schmiedebergs Arch Pharmacol. 396:365–374. 2023. View Article : Google Scholar
|
|
66
|
Zhang W, Liu M, Ji Y, Yu D, Ma C, Zhao J
and Qu P: Tanshinone IIA inhibits endometrial carcinoma growth
through the MAPK/ERK/TRIB3 pathway. Arch Biochem Biophys.
743:1096552023. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Gao M, Ou H, Jiang Y, Wang K, Peng Y,
Zhang H, Yang M and Xiao X: Tanshinone IIA attenuates
sepsis-induced immunosuppression and improves survival rate in a
mice peritonitis model. Biomed Pharmacother. 112:1086092019.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Kim WS, Kim DO, Yoon SJ, Kim MJ, Yoon SR,
Park YJ, Jung H, Kim TD, Kwon BM and Choi I: Cryptotanshinone and
tanshinone IIA enhance IL-15-induced natural killer cell
differentiation. Biochem Biophys Res Commun. 425:340–347. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Li D, Yang Z, Gao S, Zhang H and Fan G:
Tanshinone IIA ameliorates myocardial ischemia/reperfusion injury
in rats by regulation of NLRP3 inflammasome activation and Th17
cells differentiation. Acta Cir Bras. 37:e3707012022. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Godo S and Shimokawa H: Endothelial
functions. Arterioscler Thromb Vasc Biol. 37:e108–e114. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Huang KJ, Wang H, Xie WZ and Zhang HS:
Investigation of the effect of tanshinone IIA on nitric oxide
production in human vascular endothelial cells by fluorescence
imaging. Spectrochim Acta A Mol Biomol Spectrosc. 68:1180–1186.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Li YH, Xu Q, Xu WH, Guo XH, Zhang S and
Chen YD: Mechanisms of protection against diabetes-induced
impairment of endothelium-dependent vasorelaxation by Tanshinone
IIA. Biochim Biophys Acta. 1850:813–823. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Zhang XS, Ha S, Wang XL, Shi YL, Duan SS
and Li ZA: Tanshinone IIA protects dopaminergic neurons against
6-hydroxydopamine-induced neurotoxicity through
miR-153/NF-E2-related factor 2/antioxidant response element
signaling pathway. Neuroscience. 303:489–502. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Chen J, Bi Y, Chen L, Zhang Q and Xu L:
Tanshinone IIA exerts neuroprotective effects on
hippocampus-dependent cognitive impairments in diabetic rats by
attenuating ER stress-induced apoptosis. Biomed Pharmacother.
104:530–536. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Huang X, Deng H, Shen QK and Quan ZS:
Tanshinone IIA: Pharmacology, total synthesis, and progress in
structure-modifications. Curr Med Chem. 29:1959–1989. 2022.
View Article : Google Scholar
|
|
76
|
Huang X, Jin L, Deng H, Wu D, Shen QK,
Quan ZS, Zhang CH and Guo HY: Research and development of natural
product tanshinone I: Pharmacology, total synthesis, and structure
modifications. Front Pharmacol. 13:9204112022. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Ke L, Zhong C, Chen Z, Zheng Z, Li S, Chen
B, Wu Q and Yao H: Tanshinone I: Pharmacological activities,
molecular mechanisms against diseases and future perspectives.
Phytomedicine. 110:1546322023. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Luo L, Xue J, Shao Z, Zhou Z, Tang W, Liu
J, Hu H and Yang F: Recent developments in Salvia miltiorrhiza
polysaccharides: Isolation, purification, structural
characteristics and biological activities. Front Pharmacol.
14:11392012023. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Wang D, Lu C, Sun F, Cui M, Mu H, Duan J
and Geng H: A tanshinone I derivative enhances the activities of
antibiotics against Staphylococcus aureus in vitro and in vivo. Res
Microbiol. 168:46–54. 2017. View Article : Google Scholar
|
|
80
|
Zhao J, Liu H, Hong Z, Luo W, Mu W, Hou X,
Xu G, Fang Z, Ren L, Liu T, et al: Tanshinone I specifically
suppresses NLRP3 inflammasome activation by disrupting the
association of NLRP3 and ASC. Mol Med. 29:842023. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Hu C, He X, Zhang H, Hu X, Liao L, Cai M,
Lin Z, Xiang J, Jia X, Lu G, et al: Tanshinone I limits
inflammasome activation of macrophage via docking into Syk to
alleviate DSS-induced colitis in mice. Mol Immunol. 173:88–98.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Jing X, Xu Y, Cheng W, Guo S, Zou Y and He
L: Tanshinone I induces apoptosis and pro-survival autophagy in
gastric cancers. Cancer Chemother Pharmacol. 77:1171–1181. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Qian Z, Feng N and Geng A: Tanshinone I
suppresses hepatocellular carcinoma cells growth through targeting
DNA double-strand break repair. Cancer Biol Ther. 24:22299582023.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Ho JH and Hong CY: Salvianolic acids:
Small compounds with multiple mechanisms for cardiovascular
protection. J Biomed Sci. 18:302011. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Feng S, Cong H and Ji L: Salvianolic acid
a exhibits anti-inflammatory and antiarthritic effects via
inhibiting NF-κB and p38/MAPK pathways. Drug Des Devel Ther.
14:1771–1778. 2020. View Article : Google Scholar
|
|
86
|
Wu Y, Wang Z, Lin Z, Fu X, Zhan J and Yu
K: Salvianolic acid a has anti-osteoarthritis effect in vitro and
in vivo. Front Pharmacol. 11:6822020. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Zhou AM, Xiang YJ, Liu EQ, Cai CH, Wu YH,
Yang LB and Zeng CL: Salvianolic acid a inhibits platelet
activation and aggregation in patients with type 2 diabetes
mellitus. BMC Cardiovasc Disord. 20:152020. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Wang R, Song F, Li S, Wu B, Gu Y and Yuan
Y: Salvianolic acid A attenuates CCl(4)-induced liver fibrosis by
regulating the PI3K/AKT/mTOR, Bcl-2/Bax and caspase-3/cleaved
caspase-3 signaling pathways. Drug Des Devel Ther. 13:1889–1900.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Yang D, Xia X and Xi S: Salvianolic acid A
attenuates arsenic-induced ferroptosis and kidney injury via
HIF-2α/DUOX1/GPX4 and iron homeostasis. Sci Total Environ.
907:1680732024. View Article : Google Scholar
|
|
90
|
Zhu J, Guo J, Liu Z, Liu J, Yuan A, Chen
H, Qiu J, Dou X, Lu D and Le Y: Salvianolic acid A attenuates
non-alcoholic fatty liver disease by regulating the AMPK-IGFBP1
pathway. Chem Biol Interact. 400:1111622024. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Han JY, Fan JY, Horie Y, Miura S, Cui DH,
Ishii H, Hibi T, Tsuneki H and Kimura I: Ameliorating effects of
compounds derived from Salvia miltiorrhiza root extract on
microcirculatory disturbance and target organ injury by ischemia
and reperfusion. Pharmacol Ther. 117:280–295. 2008. View Article : Google Scholar
|
|
92
|
Yu XQ, Xue CC, Zhou ZW, Li CG and Zhou SF:
Tanshinone IIB, a primary active constituent from Salvia
miltiorrhiza, exerts neuroprotective effect via inhibition of
neuronal apoptosis in vitro. Phytother Res. 22:846–850. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Yu XY, Lin SG, Zhou ZW, Chen X, Liang J,
Duan W, Yu XQ, Wen JY, Chowbay B, Li CG, et al: Tanshinone IIB, a
primary active constituent from Salvia miltiorrhza, exhibits
neuro-protective activity in experimentally stroked rats. Neurosci
Lett. 417:261–265. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Ma X, Zhang L, Gao F, Jia W and Li C:
Salvia miltiorrhiza and Tanshinone IIA reduce endothelial
inflammation and atherosclerotic plaque formation through
inhibiting COX-2. Biomed Pharmacother. 167:1155012023. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Fang Y, Duan C, Chen S, Liu Z, Jiang B, Ai
W, Wang L, Xie P and Fang H: Tanshinone-IIA inhibits myocardial
infarct via decreasing of the mitochondrial apoptotic signaling
pathway in myocardiocytes. Int J Mol Med. 48:1582021. View Article : Google Scholar
|
|
96
|
Hu T, Zou HX, Le SY, Wang YR, Qiao YM,
Yuan Y, Liu JC, Lai SQ and Huang H: Tanshinone IIA confers
protection against myocardial ischemia/reperfusion injury by
inhibiting ferroptosis and apoptosis via VDAC1. Int J Mol Med.
52:1092023. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Kang YJ, Jin UH, Chang HW, Son JK, Lee SH,
Son KH, Chang YC, Lee YC and Kim CH: Inhibition of microsomal
triglyceride transfer protein expression and atherogenic risk
factor apolipoprotein B100 secretion by tanshinone IIA in HepG2
cells. Phytother Res. 22:1640–1645. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Zhang Y, Wang J, Yang S, Kou H and Liu P:
Tanshinone IIA alleviate atherosclerosis and hepatic steatosis via
down-regulation of MAPKs/NF-κB signaling pathway. Int
Immunopharmacol. 152:1144652025. View Article : Google Scholar
|
|
99
|
Hong HJ, Hsu FL, Tsai SC, Lin CH, Liu JC,
Chen JJ, Cheng TH and Chan P: Tanshinone IIA attenuates cyclic
strain-induced endothelin-1 expression in human umbilical vein
endothelial cells. Clin Exp Pharmacol Physiol. 39:63–68. 2012.
View Article : Google Scholar
|
|
100
|
Pu X, Wu Q, Yan Z, Zhou S, Zhang Q, Zhang
X, Cai Y, Liu Z, Liu R and Chang X: Tanshinone IIA modulates Sirt5
and Metll3 interaction to govern mitochondria-endoplasmic reticulum
unfolded protein response in coronary microvascular injury.
Phytomedicine. 145:1569822025. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Jin P and Cong S: LOX-1 and
atherosclerotic-related diseases. Clin Chim Acta. 491:24–29. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Chen W, Li X, Guo S, Song N, Wang J, Jia L
and Zhu A: Tanshinone IIA harmonizes the crosstalk of autophagy and
polarization in macrophages via miR-375/KLF4 pathway to attenuate
atherosclerosis. Int Immunopharmacol. 70:486–497. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Yuan L, Li Q, Zhang Z, Liu Q, Wang X and
Fan L: Tanshinone IIA inhibits the adipogenesis and inflammatory
response in ox-LDL-challenged human monocyte-derived macrophages
via regulating miR-130b/WNT5A. J Cell Biochem. 121:1400–1408. 2020.
View Article : Google Scholar
|
|
104
|
Xu S, Little PJ, Lan T, Huang Y, Le K, Wu
X, Shen X, Huang H, Cai Y, Tang F, et al: Tanshinone II-A
attenuates and stabilizes atherosclerotic plaques in
apolipoprotein-E knockout mice fed a high cholesterol diet. Arch
Biochem Biophys. 515:72–79. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Liu X, Guo CY, Ma XJ, Wu CF, Zhang Y, Sun
MY, Pan YT and Yin HJ: Anti-inflammatory effects of tanshinone IIA
on atherosclerostic vessels of ovariectomized ApoE mice are
mediated by estrogen receptor activation and through the ERK
signaling pathway. Cell Physiol Biochem. 35:1744–1755. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Tang F, Wu X, Wang T, Wang P, Li R, Zhang
H, Gao J, Chen S, Bao L, Huang H and Liu P: Tanshinone II A
attenuates atherosclerotic calcification in rat model by inhibition
of oxidative stress. Vascul Pharmacol. 46:427–438. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Feng J, Chen HW, Pi LJ, Wang J and Zhan
DQ: Protective effect of tanshinone IIA against cardiac hypertrophy
in spontaneously hypertensive rats through inhibiting the Cys-C/Wnt
signaling pathway. Oncotarget. 8:10161–10170. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Pang H, Han B, Yu T and Peng Z: The
complex regulation of tanshinone IIA in rats with
hypertension-induced left ventricular hypertrophy. PLoS One.
9:e922162014. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Fang J, Xu SW, Wang P, Tang FT, Zhou SG,
Gao J, Chen JW, Huang HQ and Liu PQ: Tanshinone II-A attenuates
cardiac fibrosis and modulates collagen metabolism in rats with
renovascular hypertension. Phytomedicine. 18:58–64. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Wang P, Wu X, Bao Y, Fang J, Zhou S, Gao
J, Pi R, Mou YG and Liu P: Tanshinone IIA prevents cardiac
remodeling through attenuating NAD (P)H oxidase-derived reactive
oxygen species production in hypertensive rats. Pharmazie.
66:517–524. 2011.PubMed/NCBI
|
|
111
|
Yu ZL, Wang JN, Wu XH, Xie HJ, Han Y, Guan
YT, Qin Y and Jiang JM: Tanshinone IIA Prevents rat basilar artery
smooth muscle cells proliferation by inactivation of PDK1 during
the development of hypertension. J Cardiovasc Pharmacol Ther.
20:563–571. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Weng YS, Wang HF, Pai PY, Jong GP, Lai CH,
Chung LC, Hsieh DJ, HsuanDay C, Kuo WW and Huang CY: Tanshinone IIA
Prevents Leu27IGF-II-induced cardiomyocyte hypertrophy mediated by
estrogen receptor and subsequent Akt activation. Am J Chin Med.
43:1567–1591. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Zhang M, Chen Y, Chen H, Shen Y, Pang L,
Wu W and Yu Z: Tanshinone IIA alleviates cardiac hypertrophy
through m6A modification of galectin-3. Bioengineered.
13:4260–4270. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Zhang Y, Zhang L, Chu W, Wang B, Zhang J,
Zhao M, Li X, Li B, Lu Y, Yang B and Shan H: Tanshinone IIA
inhibits miR-1 expression through p38 MAPK signal pathway in
post-infarction rat cardiomyocytes. Cell Physiol Biochem.
26:991–998. 2010. View Article : Google Scholar
|
|
115
|
Ren ZH, Tong YH, Xu W, Ma J and Chen Y:
Tanshinone II A attenuates inflammatory responses of rats with
myocardial infarction by reducing MCP-1 expression. Phytomedicine.
17:212–218. 2010. View Article : Google Scholar
|
|
116
|
Gao S, Yang Z, Li D, Wang B, Zheng X, Li C
and Fan G: Intervention of Tanshinone IIA on the PGK1-PDHK1 pathway
to reprogram macrophage phenotype after myocardial infarction.
Cardiovasc Drugs Ther. 38:1359–1373. 2024. View Article : Google Scholar
|
|
117
|
Yang F, Li P, Li H, Shi Q, Li S and Zhao
L: microRNA-29b mediates the antifibrotic effect of tanshinone IIA
in postinfarct cardiac remodeling. J Cardiovasc Pharmacol.
65:456–464. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Chai R, Ye Z, Xue W, Shi S, Wei Y, Hu Y
and Wu H: Tanshinone IIA inhibits cardiomyocyte pyroptosis through
TLR4/NF-κB p65 pathway after acute myocardial infarction. Front
Cell Dev Biol. 11:12529422023. View Article : Google Scholar
|
|
119
|
Chen R, Chen W, Huang X and Rui Q:
Tanshinone IIA attenuates heart failure via inhibiting oxidative
stress in myocardial infarction rats. Mol Med Rep. 23:4042021.
View Article : Google Scholar
|
|
120
|
Zhang Y, Wei L, Sun D, Cao F, Gao H, Zhao
L, Du J, Li Y and Wang H: Tanshinone IIA pretreatment protects
myocardium against ischaemia/reperfusion injury through the
phosphatidylinositol 3-kinase/Akt-dependent pathway in diabetic
rats. Diabetes Obes Metab. 12:316–322. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Li Q, Shen L, Wang Z, Jiang HP and Liu LX:
Tanshinone IIA protects against myocardial ischemia reperfusion
injury by activating the PI3K/Akt/mTOR signaling pathway. Biomed
Pharmacother. 84:106–114. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Zhang Z, He H, Qiao Y, Huang J, Wu Z, Xu
P, Yin D and He M: Tanshinone IIA Pretreatment Protects H9c2 cells
against anoxia/reoxygenation injury: Involvement of the
translocation of Bcl-2 to mitochondria mediated by 14-3-3η. Oxid
Med Cell Longev. 2018:35839212018. View Article : Google Scholar
|
|
123
|
Wang Y, Sun W, Shen L, Yu P, Shen Q, Zhou
Y, Yao L and Chen X: Tanshinone IIA protects
ischemia/reperfusion-induced cardiomyocyte injury by inhibiting the
HAS2/FGF9 Axis. Cardiol Res Pract. 2024:25816382024. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Yan K, Yu S, Gao X, Li L and Ding L:
Tanshinone IIA ameliorates myocardial ischemia-reperfusion injury
via activating HDAC1-Repressed Nrf2-xCT/Gpx4/HO-1 Axis. Chem Biol
Drug Des. 105:e700952025. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Sang Y, Du J, Zulikala D and Sang Z:
Mechanistic analysis of Tanshinone IIA's regulation of the
ATM/GADD45/ORC signaling pathway to reduce myocardial
ischemia-reperfusion injury. Front Pharmacol. 15:15103802024.
View Article : Google Scholar
|
|
126
|
Li S, Yang K, Cao W, Guo R, Liu Z, Zhang
J, Fan A, Huang Y, Ma C, Li L and Fan G: Tanshinone IIA enhances
the therapeutic efficacy of mesenchymal stem cells derived exosomes
in myocardial ischemia/reperfusion injury via up-regulating
miR-223-5p. J Control Release. 358:13–26. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Zhai P, Chen Q, Wang X, Ouyang X, Yang M,
Dong Y, Li J, Li Y, Luo S, Liu Y, et al: The combination of
Tanshinone IIA and Astragaloside IV attenuates myocardial
ischemia-reperfusion injury by inhibiting the STING pathway. Chin
Med. 19:342024. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Hong HJ, Liu JC, Chen PY, Chen JJ, Chan P
and Cheng TH: Tanshinone IIA prevents doxorubicin-induced
cardiomyocyte apoptosis through Akt-dependent pathway. Int J
Cardiol. 157:174–179. 2012. View Article : Google Scholar
|
|
129
|
Xu L, He D, Wu Y, Shen L, Wang Y and Xu Y:
Tanshinone IIA inhibits cardiomyocyte apoptosis and rescues cardiac
function during doxorubicin-induced cardiotoxicity by activating
the DAXX/MEK/ERK1/2 pathway. Phytomedicine. 107:1544712022.
View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Zhang X, Wang Q, Wang X, Chen X, Shao M,
Zhang Q, Guo D, Wu Y, Li C, Wang W and Wang Y: Tanshinone IIA
protects against heart failure post-myocardial infarction via
AMPKs/mTOR-dependent autophagy pathway. Biomed Pharmacother.
112:1085992019. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Mao S, Wang Y, Zhang M and Hinek A:
Phytoestrogen, tanshinone IIA diminishes collagen deposition and
stimulates new elastogenesis in cultures of human cardiac
fibroblasts. Exp Cell Res. 323:189–197. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Yan N, Xiao C, Wang X, Xu Z and Yang J:
Tanshinone IIA from Salvia miltiorrhiza exerts anti-fibrotic
effects on cardiac fibroblasts and rat heart tissues by suppressing
the levels of pro-fibrotic factors: The key role of miR-618. J Food
Biochem. 46:e140782022. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Huang L, Zhu J, Zheng M, Zou R, Zhou Y and
Zhu M: Tanshinone IIA protects against subclinical
lipopolysaccharide induced cardiac fibrosis in mice through
inhibition of NADPH oxidase. Int Immunopharmacol. 60:59–63. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Sun DD, Wang HC, Wang XB, Luo Y, Jin ZX,
Li ZC, Li GR and Dong MQ: Tanshinone IIA: A new activator of human
cardiac KCNQ1/KCNE1 (I(Ks)) potassium channels. Eur J Pharmacol.
590:317–321. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Wang JG, Bondy SC, Zhou L, Yang FZ, Ding
ZG, Hu Y, Tian Y, Wen PY, Luo H, Wang F, et al: Protective effect
of Tanshinone IIA against infarct size and increased HMGB1, NFκB,
GFAP and apoptosis consequent to transient middle cerebral artery
occlusion. Neurochem Res. 39:295–304. 2014. View Article : Google Scholar
|
|
136
|
Su W, Lv M, Wang D, He Y, Han H, Zhang Y,
Zhang X, Lv S and Yao L: Tanshinone IIA alleviates traumatic brain
injury by reducing ischemia-reperfusion via the miR-124-5p/FoxO1
Axis. Mediators Inflamm. 2024:74590542024. View Article : Google Scholar
|
|
137
|
Zhou C, Yu Z, Chen T, Chen Q, Zhang Y, Cai
J, Xu C and Yu L: Tanshinone IIA attenuates
cerebral-ischemia-reperfusion-induced neuroinflammation by
inhibiting the TLR4/NF-κB signaling cascade: A study integrating
network pharmacology, bioinformatics, and experimental validation.
Phytomedicine. 149:1575482025. View Article : Google Scholar
|
|
138
|
Yu H, Zhang R, Wang Q, Zhang H, Lei Z, Li
R, Shen W, Zhang Y, Lv S and Qian Y: Tanshinone IIA inhibits
microglial activation and inflammation and relieves cerebral
ischemia-reperfusion injury through TGM2/PANX1. Biochem Genet. Dec
6–2025.Epub ahead of print. View Article : Google Scholar
|
|
139
|
Yu H, Li Y, Yang Y and Qian Y, Gao X, Wang
X, Zhan P, Tang D, Qin M and Qian Y: Tanshinone IIA inhibits
neuronal ferroptosis and relieves cerebral ischemia-reperfusion
injury by regulating miR-449a/ACSL4. Metab Brain Dis. 40:2312025.
View Article : Google Scholar
|
|
140
|
Wang W, Zheng LL, Wang F, Hu ZL, Wu WN, Gu
J and Chen JG: Tanshinone IIA attenuates neuronal damage and the
impairment of long-term potentiation induced by hydrogen peroxide.
J Ethnopharmacol. 134:147–155. 2011. View Article : Google Scholar
|
|
141
|
Cai M, Guo Y, Wang S, Wei H, Sun S, Zhao G
and Dong H: Tanshinone IIA elicits neuroprotective effect through
activating the nuclear factor erythroid 2-related factor-dependent
antioxidant response. Rejuvenation Res. 20:286–297. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Liu L, Zhang X, Wang L, Yang R, Cui L, Li
M, Du W and Wang S: The neuroprotective effects of Tanshinone IIA
are associated with induced nuclear translocation of TORC1 and
upregulated expression of TORC1, pCREB and BDNF in the acute stage
of ischemic stroke. Brain Res Bull. 82:228–233. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Miao Q, Wang R, Sun X, Du S and Liu L:
Combination of puerarin and tanshinone IIA alleviates ischaemic
stroke injury in rats via activating the Nrf2/ARE signalling
pathway. Pharm Biol. 60:1022–1031. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Yang F, Ma N, Li S, Chen F, Huang X, Zhao
L and Cao L: Tanshinone IIA alleviates early brain injury after
subarachnoid hemorrhage in rats by inhibiting the activation of
NF-κB/NLRP3 inflammasome. Biol Pharm Bull. 47:279–291. 2024.
View Article : Google Scholar
|
|
145
|
Falk E: Pathogenesis of atherosclerosis. J
Am Coll Cardiol. 47(Suppl 8): C7–C12. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Xuan Y, Gao Y, Huang H, Wang X, Cai Y and
Luan QX: Tanshinone IIA attenuates atherosclerosis in
apolipoprotein E knockout mice infected with porphyromonas
gingivalis. Inflammation. 40:1631–1642. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Trepels T, Zeiher AM and Fichtlscherer S:
The endothelium and inflammation. Endothelium. 13:423–429. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Maguire JJ, Kuc RE and Davenport AP:
Vasoconstrictor activity of novel endothelin peptide, ET-1(1-31),
in human mammary and coronary arteries in vitro. Br J Pharmacol.
134:1360–1366. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Wang Y, Ruan Y and Wu S: ET-1 regulates
the human umbilical vein endothelial cell cycle by adjusting the
ERβ/FOXN1 signaling pathway. Ann Transl Med. 8:14992020. View Article : Google Scholar
|
|
150
|
Shapouri-Moghaddam A, Mohammadian S,
Vazini H, Taghadosi M, Esmaeili SA, Mardani F, Seifi B, Mohammadi
A, Afshari JT and Sahebkar A: Macrophage plasticity, polarization,
and function in health and disease. J Cell Physiol. 233:6425–6440.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Cao H, Jia Q, Yan L, Chen C, Xing S and
Shen D: Quercetin suppresses the progression of atherosclerosis by
regulating MST1-Mediated Autophagy in ox-LDL-Induced RAW264.7
macrophage foam cells. Int J Mol Sci. 20:60932019. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Rendra E, Riabov V, Mossel DM,
Sevastyanova T, Harmsen MC and Kzhyshkowska J: Reactive oxygen
species (ROS) in macrophage activation and function in diabetes.
Immunobiology. 224:242–253. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Durham AL, Speer MY, Scatena M, Giachelli
CM and Shanahan CM: Role of smooth muscle cells in vascular
calcification: Implications in atherosclerosis and arterial
stiffness. Cardiovasc Res. 114:590–600. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Elliott WJ: Systemic hypertension. Curr
Probl Cardiol. 32:201–259. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Zicha J and Vaněčková I: Altered balance
between vasoconstrictor and vasodilator systems in experimental
hypertension. Physiol Res. 73:901–928. 2024. View Article : Google Scholar
|
|
156
|
Chan P, Liu IM, Li YX, Yu WJ and Cheng JT:
Antihypertension induced by tanshinone IIA isolated from the roots
of salvia miltiorrhiza. Evid Based Complement Alternat Med.
2011:3926272011. View Article : Google Scholar :
|
|
157
|
Musumeci MB, Mastromarino V, Casenghi M,
Tini G, Francia P, Maruotti A, Romaniello A, Magrì D, Lillo R,
Adduci C, et al: Pulmonary hypertension and clinical correlates in
hypertrophic cardiomyopathy. Int J Cardiol. 248:326–332. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Zhang Z, Tang J, Song J, Xie M, Liu Y,
Dong Z, Liu X, Li X, Zhang M, Chen Y, et al: Elabela alleviates
ferroptosis, myocardial remodeling, fibrosis and heart dysfunction
in hypertensive mice by modulating the IL-6/STAT3/GPX4 signaling.
Free Radic Biol Med. 181:130–142. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Deng HW, Ye ZM, Hu RT and Qin C: The role
of long noncoding RNAs in vascular smooth muscle cell phenotype and
the pathogenesis of cardiovascular and cerebrovascular aneurysms. J
Cardiovasc Pharmacol. 84:125–135. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Gao M, Ma MM, Lu FT, Huang CC, Sun L, Lv
XF, Zhang B, Wang GL and Guan YY: Low chloride-regulated ClC-5
contributes to arterial smooth muscle cell proliferation and
cerebrovascular remodeling. Hypertension. 79:e73–e85. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Nakamura M and Sadoshima J: Mechanisms of
physiological and pathological cardiac hypertrophy. Nat Rev
Cardiol. 15:387–407. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Tu EY, Zhou YG, Wang ZH, Liang QS and Yang
GT: Effects of tanshinone II A on the myocardial hypertrophy signal
transduction system protein kinase B in rats. Chin J Integr Med.
15:365–370. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Tan X, Li J, Wang X, Chen N, Cai B, Wang
G, Shan H, Dong D, Liu Y, Li X, et al: Tanshinone IIA protects
against cardiac hypertrophy via inhibiting calcineurin/NFATc3
pathway. Int J Biol Sci. 7:383–389. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Lu L, Liu M, Sun R, Zheng Y and Zhang P:
Myocardial infarction: Symptoms and treatments. Cell Biochem
Biophys. 72:865–867. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Liu X, Zhang W, Luo J, Shi W, Zhang X, Li
Z, Qin X, Liu B and Wei Y: TRIM21 deficiency protects against
atrial inflammation and remodeling post myocardial infarction by
attenuating oxidative stress. Redox Biol. 62:1026792023. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Prabhu SD and Frangogiannis NG: The
biological basis for cardiac repair after myocardial infarction:
From inflammation to fibrosis. Circ Res. 119:91–112. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Vasudevan SO, Behl B and Rathinam VA:
Pyroptosis-induced inflammation and tissue damage. Semin Immunol.
69:1017812023. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Zhang J, Huang L, Shi X, Yang L, Hua F, Ma
J, Zhu W, Liu X, Xuan R, Shen Y, et al: Metformin protects against
myocardial ischemia-reperfusion injury and cell pyroptosis via
AMPK/NLRP3 inflammasome pathway. Aging (Albany NY). 12:24270–24287.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Bahit MC, Kochar A and Granger CB:
Post-Myocardial infarction heart failure. JACC Heart Fail.
6:179–186. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Zhu T, Chen J, Zhang M, Tang Z, Tong J,
Hao X, Li H, Xu J and Yang J: Tanshinone IIA exerts
cardioprotective effects through improving gut-brain axis
post-myocardial infarction. Cardiovasc Toxicol. 24:1317–1334. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Algoet M, Janssens S, Himmelreich U, Gsell
W, Pusovnik M, Van den Eynde J and Oosterlinck W: Myocardial
ischemia-reperfusion injury and the influence of inflammation.
Trends Cardiovasc Med. 33:357–366. 2023. View Article : Google Scholar
|
|
172
|
Zhu PC, Shen J, Qian RY, Xu J, Liu C, Hu
WM, Zhang Y and Lv LC: Effect of tanshinone IIA for myocardial
ischemia/reperfusion injury in animal model: preclinical evidence
and possible mechanisms. Front Pharmacol. 14:11652122023.
View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Zhang X, Jiang H, Zhang L, Chen C, Xing M,
Du D, Li Y, Ma Y, Ma Y and Li C: Efficacy of tanshinone IIA in rat
models with myocardial ischemia-reperfusion injury: A systematic
mini-review and meta-analysis. PeerJ. 12:e178852024. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Wang L, Qiu S, Li X, Zhang Y, Huo M and
Shi J: Myocardial-Targeting tannic cerium nanocatalyst attenuates
ischemia/reperfusion injury. Angew Chem Int Ed Engl.
62:e2023055762023. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Ma T, Wang J, Sun G, Li K, Qu H, Wang Y,
Li S and Wu B: Irisin and liraglutide combination therapy mitigates
myocardial reperfusion injury in obese rats: Role of endoplasmic
reticulum stress and apoptosis. Arch Biochem Biophys.
768:1103702025. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Dong Z, Yang L, Jiao J, Jiang Y, Li H, Yin
G, Yang P and Sun L: Aspirin in combination with gastrodin protects
cardiac function and mitigates gastric mucosal injury in response
to myocardial ischemia/reperfusion. Front Pharmacol. 13:9951022022.
View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Rogers C and Bush N: Heart failure:
Pathophysiology, diagnosis, medical treatment guidelines, and
nursing management. Nurs Clin North Am. 50:787–799. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Tanai E and Frantz S: Pathophysiology of
heart failure. Compr Physiol. 6:187–214. 2015. View Article : Google Scholar
|
|
179
|
Boorsma EM, Ter Maaten JM, Damman K, Dinh
W, Gustafsson F, Goldsmith S, Burkhoff D, Zannad F, Udelson JE and
Voors AA: Congestion in heart failure: A contemporary look at
physiology, diagnosis and treatment. Nat Rev Cardiol. 17:641–655.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Du J, Liu Y and Fu J: Autophagy and heart
failure. Adv Exp Med Biol. 1207:223–227. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Shirakabe A, Zhai P, Ikeda Y, Saito T,
Maejima Y, Hsu CP, Nomura M, Egashira K, Levine B and Sadoshima J:
Drp1-Dependent mitochondrial autophagy plays a protective role
against pressure overload-induced mitochondrial dysfunction and
heart failure. Circulation. 133:1249–1263. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Espeland T, Lunde IG, Amundsen BA,
Gullestad L and Aakhus S: Myocardial fibrosis. Tidsskr Nor
Laegeforen. Oct 12–2018.Epub ahead of print. View Article : Google Scholar
|
|
183
|
Tamiato A, Tombor LS, Fischer A,
Muhly-Reinholz M, Vanicek LR, Toğru BN, Neitz J, Glaser SF, Merten
M, Rodriguez Morales D, et al: Age-dependent RGS5 loss in pericytes
induces cardiac dysfunction and fibrosis. Circ Res. 134:1240–1255.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Deng Y, Liu X, Xie M, Zhao R, Ji L, Tang
K, Yang W, Ou W, Xie M and Li T: Obesity enables NLRP3 activation
and induces myocardial fibrosis via hyperacetylation of HADHa.
Diabetes. 72:1597–1608. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Li XM, Jiang L, Liu X, Guo YK, Li Y, Gao
Y, Han PL, Xia CC, Peng WL, Hu BY, et al: Myocardial interstitial
fibrosis and subclinical left ventricular systolic dysfunction in
type 2 diabetes mellitus patients with obesity: A 3.0 T MRI study.
Cardiovasc Diabetol. 25:222025. View Article : Google Scholar
|
|
186
|
Fu DG: Cardiac arrhythmias: Diagnosis,
symptoms, and treatments. Cell Biochem Biophys. 73:291–296. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Shan H, Li X, Pan Z, Zhang L, Cai B, Zhang
Y, Xu C, Chu W, Qiao G, Li B, et al: Tanshinone IIA protects
against sudden cardiac death induced by lethal arrhythmias via
repression of microRNA-1. Br J Pharmacol. 158:1227–1235. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
188
|
He Z, Sun C, Xu Y and Cheng D: Reduction
of atrial fibrillation by Tanshinone IIA in chronic heart failure.
Biomed Pharmacother. 84:1760–1767. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Jurcau A and Simion A: Neuroinflammation
in cerebral ischemia and ischemia/reperfusion injuries: From
pathophysiology to therapeutic strategies. Int J Mol Sci.
23:142021. View Article : Google Scholar
|
|
190
|
Jiang F, Xu C, Fan X, Yang S, Fan W, Li M,
Song J, Wei W, Chen H, Zhong D and Li G: MyD88 inhibition
attenuates cerebral ischemia-reperfusion injury by regulating the
inflammatory response and reducing blood-brain barrier damage.
Neuroscience. 549:121–137. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Chen X, Zhou ZW, Xue CC, Li XX and Zhou
SF: Role of P-glycoprotein in restricting the brain penetration of
tanshinone IIA, a major active constituent from the root of Salvia
miltiorrhiza Bunge, across the blood-brain barrier. Xenobiotica.
37:635–678. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Guzik A and Bushnell C: Stroke
epidemiology and risk factor management. Continuum (Minneap Minn).
23(1, Cerebrovascular Disease): 15–39. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Zhao Y, Zhang X, Chen X and Wei Y:
Neuronal injuries in cerebral infarction and ischemic stroke: From
mechanisms to treatment (Review). Int J Mol Med. 49:152022.
View Article : Google Scholar :
|
|
194
|
Campbell BCV, De Silva DA, Macleod MR,
Coutts SB, Schwamm LH, Davis SM and Donnan GA: Ischaemic stroke.
Nat Rev Dis Primers. 5:702019. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Fang M, Huang DR, Zhang JW, Liao WJ, Wu F
and Liu YW: Tanshinone Ⅱ_A exerts anti-hepatocellular carcinoma
effects by inhibiting oxidative stress via PI3K/Akt and Nrf2/HO-1
signaling pathway. Zhongguo Zhong Yao Za Zhi. 49:6724–6734. 2024.In
Chinese.
|
|
196
|
Liu H, Wang L, Hu M, Hua J, Lian X, Lian C
and Zhang J: Brusatol regulates ferroptosis of ovarian cancer
through the Nrf2/HO-1/NQO1 and AKT/mTOR double signaling pathways.
Curr Pharm Des. Aug 19–2025.Epub ahead of print. View Article : Google Scholar
|
|
197
|
Fu C, Wu Y, Liu S, Luo C, Lu Y, Liu M,
Wang L, Zhang Y and Liu X: Rehmannioside A improves cognitive
impairment and alleviates ferroptosis via activating PI3K/AKT/Nrf2
and SLC7A11/GPX4 signaling pathway after ischemia. J
Ethnopharmacol. 289:1150212022. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Wu X, Wang J, Song L, Guan Y, Cao C, Cui
Y, Zhang Y and Liu C: Catalpol weakens depressive-like behavior in
mice with streptozotocin-induced hyperglycemia via
PI3K/AKT/Nrf2/HO-1 signaling pathway. Neuroscience. 473:102–118.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Chen Q, Wang Q, Zhao Y, Xie X, Feng H, Wei
Y, Yu M, Pan X and Hu T: Flavonoids from Polygonum hydropiper L.
regulate PCV2-induced oxidative stress of RAW264.7 cells via
Pi3k/AKT and Nrf2/HO-1 signaling pathways. Sci Rep. 15:291122025.
View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Huang Q, Zhang C, Dong S, Han J, Qu S, Xie
T, Zhao H and Shi Y: Asafoetida exerts neuroprotective effect on
oxidative stress induced apoptosis through PI3K/Akt/GSK3β/Nrf2/HO-1
pathway. Chin Med. 17:832022. View Article : Google Scholar
|
|
201
|
Hannawi Y: Cerebral small vessel disease:
A review of the pathophysiological mechanisms. Transl Stroke Res.
15:1050–1069. 2024. View Article : Google Scholar
|
|
202
|
Katusic ZS, d'Uscio LV and He T:
Cerebrovascular endothelial dysfunction: Role of BACE1.
Arterioscler Thromb Vasc Biol. 44:1737–1747. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
You N, Liu G, Yu M, Chen W, Fei X, Sun T,
Han M, Qin Z, Wei Z and Wang D: Reconceptualizing
Endothelial-to-mesenchymal transition in atherosclerosis: Signaling
pathways and prospective targeting strategies. J Adv Res.
77:419–441. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Waters ES, Kaiser EE, Yang X, Fagan MM,
Scheulin KM, Jeon JH, Shin SK, Kinder HA, Kumar A, Platt SR, et al:
Intracisternal administration of tanshinone IIA-loaded
nanoparticles leads to reduced tissue injury and functional
deficits in a porcine model of ischemic stroke. IBRO Neurosci Rep.
10:18–30. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Zhao Y, Wang J, Zhang Z, Kong L, Liu M,
Chen M and Gao L: A ROS-responsive TPP-modified tanshinone IIA
micelle improves DOX-induced heart failure. Int J Pharm.
672:1253182025. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Zhang W, Li J, Liu J, Wu Z, Xu Y and Wang
J: Tanshinone IIA-loaded reconstituted high density lipoproteins:
Atherosclerotic plaque targeting mechanism in a foam cell model and
pharmacokinetics in rabbits. Pharmazie. 67:324–330. 2012.PubMed/NCBI
|
|
207
|
Zhang W, He H, Liu J, Wang J, Zhang S,
Zhang S and Wu Z: Pharmacokinetics and atherosclerotic lesions
targeting effects of tanshinone IIA discoidal and spherical
biomimetic high density lipoproteins. Biomaterials. 34:306–319.
2013. View Article : Google Scholar
|
|
208
|
Zhang S, Li J, Hu S, Wu F and Zhang X:
Triphenylphosphonium and D-α-tocopheryl polyethylene glycol 1000
succinate-modified, tanshinone IIA-loaded lipid-polymeric
nanocarriers for the targeted therapy of myocardial infarction. Int
J Nanomedicine. 13:4045–4057. 2018. View Article : Google Scholar
|
|
209
|
Fan L, Qu H, Wang B, Li HZ, Yang WW, Guo
H, Zhang SS, Long LZ, Liu Y, Zhou G, et al: Delivery of liquid
metal particles and tanshinone IIA into the pericardial cavity for
myocardial infarction treatment. J Mater Chem B. 12:11916–11925.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Ma H, Hu ZC, Long Y, Cheng LC, Zhao CY and
Shao MK: Tanshinone IIA microemulsion protects against cerebral
ischemia reperfusion injury via regulating H3K18ac and H4K8ac in
vivo and in vitro. Am J Chin Med. 50:1845–1868. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Liu X, Ye M, An C, Pan L and Ji L: The
effect of cationic albumin-conjugated PEGylated tanshinone IIA
nanoparticles on neuronal signal pathways and neuroprotection in
cerebral ischemia. Biomaterials. 34:6893–6905. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Wang D, Lv L, Xu Y, Jiang K, Chen F, Qian
J, Chen M, Liu G and Xiang Y: Cardioprotection of Panax notoginseng
saponins against acute myocardial infarction and heart failure
through inducing autophagy. Biomed Pharmacother. 136:1112872021.
View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Liang Y, Chen B, Liang D, Quan X, Gu R,
Meng Z, Gan H, Wu Z, Sun Y, Liu S and Dou G: Pharmacological
effects of astragaloside IV: A review. Molecules. 28:61182023.
View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Zheng Q, Bao XY, Zhu PC, Tong Q, Zheng GQ
and Wang Y: Ginsenoside Rb1 for myocardial ischemia/reperfusion
injury: Preclinical evidence and possible mechanisms. Oxid Med Cell
Longev. 2017:63136252017. View Article : Google Scholar
|
|
215
|
Ma J, Hou D, Wei Z, Zhu J, Lu H, Li Z,
Wang X, Li Y, Qiao G and Liu N: Tanshinone IIA attenuates cerebral
aneurysm formation by inhibiting the NF-κB-mediated inflammatory
response. Mol Med Rep. 20:1621–1628. 2019.PubMed/NCBI
|
|
216
|
Lu Y, Yan Y and Liu X: Effects of
alprostadil combined with tanshinone IIa injection on
microcirculation disorder, outcomes, and cardiac function in AMI
patients after PCI. Ann Palliat Med. 10:97–103. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Xu Q, Li H, Zhang X, Ding H and Cao J:
Tanshinone IIA elevates serum soluble klotho levels and decreases
cardiovascular events in patients on maintenance hemodialysis: a
prospective before-after study. Ann Palliat Med. 9:2131–2140. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
218
|
Zhang M, Liu Y, Sun X, Zhang X and Hua L:
Salvia miltiorrhiza adjuvant therapy facilitates cardiac function
recovery in patients with myocardial infarction. Pak J Pharm Sci.
38:45–53. 2025.PubMed/NCBI
|
|
219
|
Mao S, Taylor S, Chen Q, Zhang M and Hinek
A: Sodium tanshinone IIA sulfonate prevents the adverse left
ventricular remodelling: Focus on polymorphonuclear
neutrophil-derived granule components. J Cell Mol Med.
23:4592–4600. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
220
|
Mao S, Wang L, Zhao X, Guo L, Lin Q, Wang
X, Dai X, Shang H, Zhang M and Hinek A: Efficacy of sodium
tanshinone IIA sulfonate in patients with Non-ST elevation acute
coronary syndrome undergoing percutaneous coronary intervention:
results from a multicentre, controlled, randomized trial.
Cardiovasc Drugs Ther. 35:321–329. 2021. View Article : Google Scholar
|
|
221
|
Zhou ZY, Zhao WR, Zhang J, Chen XL and
Tang JY: Sodium tanshinone IIA sulfonate: A review of
pharmacological activity and pharmacokinetics. Biomed Pharmacother.
118:1093622019. View Article : Google Scholar : PubMed/NCBI
|
|
222
|
Guan R, Yao H, Li Z, Qian J, Yuan L, Cai
Z, Ding M, Liu W, Xu J, Li Y, et al: Sodium tanshinone IIA
sulfonate attenuates cigarette smoke extract-induced mitochondrial
dysfunction, oxidative stress, and apoptosis in alveolar epithelial
cells by enhancing SIRT1 pathway. Toxicol Sci. 183:352–362. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
223
|
Lan J, Li K, Gresham A and Miao J:
Tanshinone IIA sodium sulfonate attenuates inflammation by
upregulating circ-Sirt1 and inhibiting the entry of NF-κB into the
nucleus. Eur J Pharmacol. 914:1746932022. View Article : Google Scholar
|
|
224
|
Wu P, Du Y, Xu Z, Zhang S, Liu J, Aa N and
Yang Z: Protective effects of sodium tanshinone IIA sulfonate on
cardiac function after myocardial infarction in mice. Am J Transl
Res. 11:351–360. 2019.PubMed/NCBI
|
|
225
|
Zhong L, Ding W, Zeng Q, He B, Zhang H,
Wang L, Fan J, He S, Zhang Y and Wei A: Sodium tanshinone IIA
sulfonate attenuates erectile dysfunction in rats with
hyperlipidemia. Oxid Med Cell Longev. 2020:72869582020.PubMed/NCBI
|
|
226
|
Li S, Jiao Y, Wang H, Shang Q, Lu F, Huang
L, Liu J, Xu H and Chen K: Sodium tanshinone IIA sulfate adjunct
therapy reduces high-sensitivity C-reactive protein level in
coronary artery disease patients: A randomized controlled trial.
Sci Rep. 7:174512017. View Article : Google Scholar : PubMed/NCBI
|
|
227
|
Ji B, Zhou F, Han L, Yang J, Fan H, Li S,
Li J, Zhang X, Wang X, Chen X and Xu Y: Sodium tanshinone IIA
sulfonate enhances effectiveness Rt-PA treatment in acute ischemic
stroke patients associated with ameliorating blood-brain barrier
damage. Transl Stroke Res. 8:334–340. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
228
|
Wu Q, Guan YB, Zhang KJ, Li L and Zhou Y:
Tanshinone IIA mediates protection from diabetes kidney disease by
inhibiting oxidative stress induced pyroptosis. J Ethnopharmacol.
316:1166672023. View Article : Google Scholar : PubMed/NCBI
|
|
229
|
Xu Z, Cai K, Su SL, Zhu Y, Liu F and Duan
JA: Salvianolic acid B and tanshinone IIA synergistically improve
early diabetic nephropathy through regulating PI3K/Akt/NF-κB
signaling pathway. J Ethnopharmacol. 319:1173562024. View Article : Google Scholar
|
|
230
|
Chen S, Li P, Shi K, Tang S, Zhang W, Peng
C, Li T, Xie H, Liu C and Zhou J: Tanshinone IIA promotes
ferroptosis in cutaneous melanoma via STAT1-mediated upregulation
of PTGS2 expression. Phytomedicine. 141:1567022025. View Article : Google Scholar : PubMed/NCBI
|
|
231
|
Zhang H, Long M, Wu Z, Han X and Yu Y:
Sodium tanshinone IIA silate as an add-on therapy in patients with
unstable angina pectoris. J Thorac Dis. 6:1794–1799. 2014.
|
|
232
|
Wu X, Fan M, Wei S and Guo D: The efficacy
and safety of sodium tanshinone ⅡA sulfonate injection in the
treatment of unstable angina pectoris: A systematic review and
meta-analysis. PLoS One. 18:e02908412023. View Article : Google Scholar
|
|
233
|
Liu F, Zhao Q, Sun L, Yan M, Gao M, Wang
H, Li Z, Zhou D, Li C, Li T, et al: A systematic review and
meta-analysis of randomized controlled trials on the efficacy and
safety of tanshinone IIA sodium sulfonate injection as adjunctive
therapy for stroke. J Ethnopharmacol. 353:1204132025. View Article : Google Scholar : PubMed/NCBI
|
|
234
|
Zhao R, Wang H, Li S, Wang L, Lei X, Peng
P, Du L and Dong J: Tanshinone IIA@β-cyclodextrin encapsulated with
Eucommia ulmoides rubber/acetylated starch film as novel oral
delivery system for therapy of orthotopic colon cancer. Carbohydr
Polym. 353:1232952025. View Article : Google Scholar
|
